Australia markets close in 5 hours 18 minutes

WuXi Biologics (Cayman) Inc. (WXXWY)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
19.30-0.42 (-2.13%)
At close: 03:58PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close19.72
Open19.72
Bid0.00 x 0
Ask0.00 x 0
Day's range19.16 - 19.72
52-week range10.50 - 38.00
Volume352,088
Avg. volume211,819
Market cap40.935B
Beta (5Y monthly)1.14
PE ratio (TTM)83.91
EPS (TTM)0.23
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • PR Newswire

    WuXi Biologics Launches First Commercial Drug Product Facility for Pre-Filled Syringes

    WuXi Biologics ("WuXi Bio") (2269.HK), a global CRDMO service company, announced it has successfully launched the GMP operation of its new drug product facility DP5 located in Wuxi, China. The DP5 is the ninth operational drug product facility in the global network of WuXi Biologics.

  • PR Newswire

    WuXi Biologics' 2021 ESG Report Reveals Company's Strong Commitment to Overall Sustainability

    WuXi Biologics ("WuXi Bio") (2269.HK), a global Contract Research, Development and Manufacturing Organization (CRDMO) service company, published its Environmental, Social and Governance (ESG) Report of 2021. It comprehensively introduces what the company has achieved on greening development, enabling clients, giving back to society and responsible governance in the past year.

  • PR Newswire

    WuXi Biologics Receives Bioprocessing Excellence Award from IMAPAC

    WuXi Biologics ("WuXi Bio") (2269.HK), a global Contract Research, Development and Manufacturing Organization (CRDMO) service company, today announced that the company received the award for Bioprocessing Excellence in Viral Clearance and Safety at the Asia-Pacific Bioprocessing Excellence Awards (ABEA) 2022 event. This marks the second consecutive year that WuXi Bio has received this award from IMAPAC, a leading consulting firm in biopharmaceutical industry.